UNASSIGNED: @entity1990 ( @entity1990 ) signaling has been implicated in innate immunity and acute @entity32 following @entity647 ( @entity647 ). As such, modulating inflammatory response through @entity1990 represents an attractive therapeutic approach to treat @entity647 . Increasing evidence demonstrates that hyaluronan (HA) can modulate @entity1990 activation and has shown early promise as a therapeutic agent in @entity647 . However, the mechanism associated with HA has not been fully elucidated. In the current study, we sought to determine the effects of HA on lipopolysaccharide (LPS)-induced inflammatory response and gain insights into the mechanism of action in @entity19 with intratracheal instillation of LPS. Our results demonstrate that in contrast to @entity19 challenged with LPS, pretreatment with HA significantly inhibited inflammatory cell recruitment, @entity651 and suppressed the level of cytokine/chemokine in bronchial alveolar lavage fluid (BALF). Investigation of the mechanism responsible for inhibition of LPS activation showed HA treatment significantly inhibited the nuclear translocation of NF-kB p65 and protein expression of myeloid differentiation primary response protein ( @entity5001 ) and @entity7485 ( @entity7485 ) and @entity1995 , @entity42216 activation in lung tissue. Furthermore, we compared the protection effect of HA in @entity1990 -deficient @entity19 with those of genetically matched @entity164 ( @entity164 ) @entity19 in an acute model of @entity651 . However, in @entity1990 -deficient @entity19 , HA pretreatment before LPS instillation fail to affect the LPS response. Therefore, our findings suggest that HA pretreatment attenuated LPS-induced @entity647 and the anti-inflammatory function of HA was partial dependent on @entity1990 , which shed new light on potential elements that regulate the @entity651 response.

Hyaluronan ameliorates LPS-induced XXXX in @entity19 via Toll-like receptor (TLR) 4-dependent signaling pathways.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity42216 :: ('26419;26413', 'Gene') :: ['JNK and ERK'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity7485 :: ('106759(Tax:10090)', 'Gene') :: ['TRIF', 'TIR-domain-containing adapter-inducing interferon-b'] @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury', 'attenuated lung injury'] @entity5001 :: ('17874(Tax:10090)', 'Gene') :: ['MyD88'] @entity164 :: ('MESH:D017827', 'Disease') :: ['WT', 'wild type'] @entity1990 :: ('21898(Tax:10090)', 'Gene') :: ['TLR4', 'Toll-like receptor-4'] @entity1995 :: ('26416(Tax:10090)', 'Gene') :: ['p38 MAPK'] @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury', 'ALI']
@entity647 :: (MESH:D055371,Disease) :: ['acute lung injury']
